Completed PHASE3 INTERVENTIONAL NCT00144469

A Study of Peginterferon Alfa-2a in Combination With Ribavirin in Patients With Chronic Hepatitis C

A Phase III Study of Ro25-8310 (Peginterferon Alfa-2a) in Combination With Ro20-9963 (Ribavirin) in Patients With Chronic Hepatitis C

Sponsor: Chugai Pharmaceutical

Conditions Chronic Hepatitis C

Interventions peginterferon alfa-2a rivavirin

Updated 5 times since 2017 Last updated: Jan 29, 2009 Started: May 31, 2002 Completion: Mar 31, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Chronic Hepatitis C, this trial is completed. The trial is conducted by Chugai Pharmaceutical and has accumulated 5 data snapshots since 2002. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

May 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Chugai Pharmaceutical

Data source: Chugai Pharmaceutical

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.